Tech Company Financing Transactions
Carmot Therapeutics Funding Round
The Column Group and private investors joined a Series A venture round for Carmot Therapeutics. The round was announced on 4/12/2010.
Transaction Overview
Company Name
Announced On
4/12/2010
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
The Column Group (Lead Investor)
Proceeds Purpose
Carmot will use the capital to advance its proprietary drug-discovery platform, Chemotype Evolution, a novel lead finding technology that employs target-directed compound libraries generated through a unique fragment-assembly approach.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
740 Heinz Ave.
Berkeley, CA 94710
USA
Berkeley, CA 94710
USA
Phone
Website
Email Address
Overview
Carmot Therapeutics develops drugs to treat inflammatory, metabolic and neurological diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stig Hansen
Chief Medical Officer
Allan Gordon
VP - Bus. Development
James Watson
Browse more venture capital transactions:
Prev: 4/12/2010: EdgeCast Networks venture capital transaction
Next: 4/13/2010: Qcept Technologies venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs